glp-1 receptor agonists muscle mass preservation 2025 Beyond weight loss: Preserving during pharmacotherapy of obesity GLP-1 Receptor Agonist Market Size
Description
Are not willing or able to make the appropriate lifestyle changes that should accompany a GLP1
Sitagliptin was approved in 2006, but in contrast to the GLP-1 agonists, DPP4 inhibitors have little or no effect on body weight
Sitagliptin is another weapon in the arsenal of oral antihyperglycemic agents
Rotating injection sites between abdomen, thigh, and upper arm reduces reaction incidence
